Latest KRAS Stories
A mutant protein found in nearly all pancreatic cancers plays a role not only in the cancer's development but in its continued growth.
Scientists have connected two signature characteristics of pancreatic cancer, identifying a self-perpetuating "vicious cycle" of molecular activity and a new potential target for drugs to treat one of the most lehal forms of cancer.
Doctors and researchers of Hospital del Mar and its research institute, the IMIM, have lead a study describing a new pharmacological resistance to cancer.
Until now, researchers have not examined never-smokers as extensively as they have smokers as potential lung cancer patients.
The investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene.
Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory."
Multicentric carcinogenesis with the same genetic mutation appears to occur in lung adenocarcinoma.
Smoking is a well-known risk factor for lung cancer, but about 25% of all lung cancer patients have never smoked. According to this study, a gene fusion event could explain a significant proportion of these lung cancer cases, and may serve as a target for new therapies.
Smoking is a well-known risk factor for lung cancer, but nearly 25% of all lung cancer patients have never smoked.
- totally perplexed and mixed up.